The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer (original) (raw)

Abstract

Levels of mucin-like carcinoma-associated antigen (MCA), CA15.3 and carcinoembryonic antigen (CEA) were measured in consecutive serum samples of 40 women with metastatic breast cancer. A change in antigen level of more than 25%, either an increase or a decrease, was considered to predict progressive or responsive disease respectively. A change of less than 25% was considered to predict stable disease. MCA, CA15.3 and CEA were elevated in the serum of 68%, 76% and 48% of the patients respectively (P<0.05). The overall prediction of clinical course was similar for all three markers. A more than 25% increase of MCA, CA15.3, and CEA was observed in 61%, 54% and 36% respectively. The predictive value of a more than 25% increase was high for all three markers: 94%, 94%, 83%. Changes in marker levels were correlated with each other. Logistic regression analysis showed that combining MCA and CA15.3 did not improve the prediction further. In conclusion, these tumour markers may help in evaluating the disease course and there is no advantage in combining MCA and CA15.3.

Access this article

Log in via an institution

Subscribe and save

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

• Beard DB, Haskell CM (1986) Carcinoembryonic antigen in breast cancer, clinical review. Am J Med 80:40–245
  Google Scholar
• Bieglmayer C, Szopesi T, Neunteufel W, Nowotny C (1989) MCA, a monoclonal-antibody-defined breast tumor associated antigen and its relation to CA15.3. Tumor Biol 10:232–242
  Google Scholar
• Colomer R, Ruibal A, Salvader L (1989) Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64:1674–1682
  Google Scholar
• Fletcher RH (1986) Carcinoembryonic antigen. Ann Intern Med 104:66–73
  Google Scholar
• Haagensen DE, Kister SJ, Vandevoorde JP, Gates JB, Smart EK, Hansen HJ, Wells SA (1978) Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer 42:1512–1519
  Google Scholar
• Hayes DF, Zurawski VR, Kufe DW (1986) Comparison of circulating CA15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542–1550
  Google Scholar
• Linsley PS, Brown JP, Magnani JC, Horn D (1988) Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Cancer Res 48:2138–2148
  Google Scholar
• Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, Falkson HC, Chang AYC (1986) Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 4:46–56
  Google Scholar
• Miserez AR, Günez I, Müller-Brand J, Walther E, Fridrich R, Macke H (1991) Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3. Eur J Cancer 27:126–131
  Google Scholar
• Pons-Anicet DMF, Krebs BP, Mira R, Namer M (1987) Value of CA15.3 in the follow up of breast cancer patients. Br J Cancer 55:567–569
  Google Scholar
• Stahli C, Caravatti M, Aeschbacher M, Kocyba C, Takacs B, Carmann H (1988) Mucin like carcinoma associated antigen defined by three monoclonal antibodies against different epitopes. Cancer Res 48:6799–6802
  Google Scholar
• Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW (1988) Comparison of CA15.3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107–4112
  Google Scholar
• Tormey DC, Waalkes TP (1978) Clinical correlation between CEA and breast cancer. Cancer 42:1507–1511
  Google Scholar
• Waalkes TP, Enterline JP, Sharper JH, Abeloff MD, Ettinger DS (1984) Biological markers for breast carcinoma. Cancer 53:644–651
  Google Scholar
• Wit R de, Bakker PJM, Hoek FJ, Veenhof CHN (1991) The value of MCA, CA15-3, CEA and CA125 to discriminate between metastatic breast cancer and metastatic adenocarcinoma of other primairy site. J Intern Med 229:463–466
  Google Scholar

Download references

Author information

Authors and Affiliations

1. Laboratoire de “Rythmes Biologiques et Chronotherapeutique”. I.C.I.G., Hôpital Paul Brousse, France
   Petra Deprés-Brummer & Moshe Itzhaki
2. Department of Medical Oncology, Academic Medical Centre, Amsterdam, The Netherlands
   Piet J. M. Bakker & Kees H. N. Veenhof
3. Department of Clinical Chemistry, Academic Medical Centre, Amsterdam, The Netherlands
   Frans J. Hoek
4. Department of Medical Oncology, Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek, P.O. Box 5201, 3008 AE, Rotterdam, The Netherlands
   Ronald de Wit

Authors

1. Petra Deprés-Brummer
   You can also search for this author inPubMed Google Scholar
2. Moshe Itzhaki
   You can also search for this author inPubMed Google Scholar
3. Piet J. M. Bakker
   You can also search for this author inPubMed Google Scholar
4. Frans J. Hoek
   You can also search for this author inPubMed Google Scholar
5. Kees H. N. Veenhof
   You can also search for this author inPubMed Google Scholar
6. Ronald de Wit
   You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Deprés-Brummer, P., Itzhaki, M., Bakker, P.J.M. et al. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.J Cancer Res Clin Oncol 121, 419–422 (1995). https://doi.org/10.1007/BF01212949

Download citation

• Received: 11 July 1994
• Accepted: 27 February 1995
• Issue Date: July 1995
• DOI: https://doi.org/10.1007/BF01212949

Key words